342 related articles for article (PubMed ID: 23621668)
1. Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain.
Tanasescu R; Constantinescu CS
Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1219-28. PubMed ID: 23621668
[TBL] [Abstract][Full Text] [Related]
2. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
Bazinski H; Jensen HB; Stenager E
Ugeskr Laeger; 2015 May; 177(20):956-60. PubMed ID: 26535431
[TBL] [Abstract][Full Text] [Related]
3. Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.
Podda G; Constantinescu CS
Expert Opin Biol Ther; 2012 Nov; 12(11):1517-31. PubMed ID: 22954177
[TBL] [Abstract][Full Text] [Related]
4. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
Basinski H; Jensen HB; Stenager E
Ugeskr Laeger; 2014 Mar; 176(12A):. PubMed ID: 25350886
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.
Moreno Torres I; Sanchez AJ; Garcia-Merino A
Expert Rev Neurother; 2014 Nov; 14(11):1243-50. PubMed ID: 25331416
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years" accumulated evidence from clinical trials.
Prieto González JM; Vila Silván C
Expert Rev Neurother; 2021 Jul; 21(7):755-778. PubMed ID: 34092180
[No Abstract] [Full Text] [Related]
7. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.
Flachenecker P; Henze T; Zettl UK
Eur Neurol; 2014; 71(5-6):271-9. PubMed ID: 24525548
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports.
Prieto González JM; Vila Silván C
Expert Rev Neurother; 2021 May; 21(5):547-558. PubMed ID: 33749480
[TBL] [Abstract][Full Text] [Related]
9. Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosis.
Gajofatto A
Mult Scler Relat Disord; 2016 Jul; 8():64-5. PubMed ID: 27456876
[TBL] [Abstract][Full Text] [Related]
10. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
Barnes MP
Expert Opin Pharmacother; 2006 Apr; 7(5):607-15. PubMed ID: 16553576
[TBL] [Abstract][Full Text] [Related]
11. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
12. Sativex for the management of multiple sclerosis symptoms.
Perras C
Issues Emerg Health Technol; 2005 Sep; (72):1-4. PubMed ID: 16317825
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic use of cannabinoids: Forensic aspects.
Indorato F; Liberto A; Ledda C; Romano G; Barbera N
Forensic Sci Int; 2016 Aug; 265():200-3. PubMed ID: 27038587
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis.
Carod-Artal FJ; Adjamian P; Vila Silván C; Bagul M; Gasperini C
Expert Rev Neurother; 2022 Jun; 22(6):499-511. PubMed ID: 35582858
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
Rice J; Cameron M
Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain.
Iskedjian M; Bereza B; Gordon A; Piwko C; Einarson TR
Curr Med Res Opin; 2007 Jan; 23(1):17-24. PubMed ID: 17257464
[TBL] [Abstract][Full Text] [Related]
17. Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience.
D'hooghe M; Willekens B; Delvaux V; D'haeseleer M; Guillaume D; Laureys G; Nagels G; Vanderdonckt P; Van Pesch V; Popescu V
BMC Neurol; 2021 Jun; 21(1):227. PubMed ID: 34157999
[TBL] [Abstract][Full Text] [Related]
18. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment.
Serpell M; Ratcliffe S; Hovorka J; Schofield M; Taylor L; Lauder H; Ehler E
Eur J Pain; 2014 Aug; 18(7):999-1012. PubMed ID: 24420962
[TBL] [Abstract][Full Text] [Related]
19. Cannabis and multiple sclerosis.
Fragoso YD; Carra A; Macias MA
Expert Rev Neurother; 2020 Aug; 20(8):849-854. PubMed ID: 32515670
[TBL] [Abstract][Full Text] [Related]
20. The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray).
Grimaldi AE; De Giglio L; Haggiag S; Bianco A; Cortese A; Crisafulli SG; Monteleone F; Marfia G; Prosperini L; Galgani S; Mirabella M; Centonze D; Pozzilli C; Castelli L
PLoS One; 2019; 14(7):e0219670. PubMed ID: 31361750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]